HRP20220512T1 - Supstituirani pirazolopirimidini kao aktivatori glukocerebrozidaze - Google Patents
Supstituirani pirazolopirimidini kao aktivatori glukocerebrozidaze Download PDFInfo
- Publication number
- HRP20220512T1 HRP20220512T1 HRP20220512TT HRP20220512T HRP20220512T1 HR P20220512 T1 HRP20220512 T1 HR P20220512T1 HR P20220512T T HRP20220512T T HR P20220512TT HR P20220512 T HRP20220512 T HR P20220512T HR P20220512 T1 HRP20220512 T1 HR P20220512T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- c2alkyl
- pharmaceutical composition
- phenyl
- c4alkyl
- Prior art date
Links
- 108010017544 Glucosylceramidase Proteins 0.000 title claims 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
- 102000004547 Glucosylceramidase Human genes 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- -1 cyano, nitro, amino Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 101150028412 GBA gene Proteins 0.000 claims 2
- 208000015872 Gaucher disease Diseases 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- IDVNKENDKSWSGM-UHFFFAOYSA-N 5,7-dimethyl-n-quinolin-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC=CC2=NC(NC(=O)C=3C=NN4C(C)=CC(=NC4=3)C)=CC=C21 IDVNKENDKSWSGM-UHFFFAOYSA-N 0.000 claims 1
- CWYOCWBZXYMRSX-UHFFFAOYSA-N 5,7-dimethyl-n-quinolin-3-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C=3C=NN4C(C)=CC(=NC4=3)C)=CN=C21 CWYOCWBZXYMRSX-UHFFFAOYSA-N 0.000 claims 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- MUEZEYDZQXQLNT-UHFFFAOYSA-N chembl1876337 Chemical compound N1=CC=C2C(NC(=O)C3=C4NC(=C)C=C(N4N=C3)C)=CC=CC2=C1 MUEZEYDZQXQLNT-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- MCQYBGOYJAACFA-UHFFFAOYSA-N n-(4-tert-butylcyclohexyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1CCC(C(C)(C)C)CC1 MCQYBGOYJAACFA-UHFFFAOYSA-N 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42094610P | 2010-12-08 | 2010-12-08 | |
| EP18165005.2A EP3366688B1 (en) | 2010-12-08 | 2011-12-08 | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220512T1 true HRP20220512T1 (hr) | 2022-05-27 |
Family
ID=45498099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220512TT HRP20220512T1 (hr) | 2010-12-08 | 2011-12-08 | Supstituirani pirazolopirimidini kao aktivatori glukocerebrozidaze |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9353117B2 (enExample) |
| EP (2) | EP2649075B1 (enExample) |
| JP (1) | JP6154746B2 (enExample) |
| KR (1) | KR101931224B1 (enExample) |
| CN (1) | CN103534255B (enExample) |
| AU (1) | AU2011338377B2 (enExample) |
| BR (1) | BR112013014242B1 (enExample) |
| CA (1) | CA2820362C (enExample) |
| CY (1) | CY1125186T1 (enExample) |
| DK (2) | DK3366688T3 (enExample) |
| ES (2) | ES2912284T3 (enExample) |
| HR (1) | HRP20220512T1 (enExample) |
| HU (1) | HUE038635T2 (enExample) |
| IL (2) | IL226767B (enExample) |
| LT (1) | LT3366688T (enExample) |
| MX (2) | MX385600B (enExample) |
| PL (2) | PL3366688T3 (enExample) |
| PT (2) | PT2649075T (enExample) |
| RS (1) | RS63320B1 (enExample) |
| RU (1) | RU2603637C2 (enExample) |
| SI (2) | SI3366688T1 (enExample) |
| TR (1) | TR201810523T4 (enExample) |
| WO (1) | WO2012078855A1 (enExample) |
| ZA (1) | ZA201304215B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013014242B1 (pt) | 2010-12-08 | 2022-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composição farmacêutica e composto ou seu sal farmaceuticamente aceitável |
| JP6061922B2 (ja) * | 2011-06-22 | 2017-01-18 | ザ ジェネラル ホスピタル コーポレイション | プロテイノパチーの処置方法 |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| CA2839703A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| PE20140868A1 (es) | 2011-06-24 | 2014-07-18 | Amgen Inc | Antagonistas trpm8 y su uso en tratamientos |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
| JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PL3077397T3 (pl) | 2013-12-06 | 2020-04-30 | Vertex Pharmaceuticals Inc. | Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne |
| CN113620958A (zh) | 2014-03-19 | 2021-11-09 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
| PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| JP2017533235A (ja) | 2014-11-03 | 2017-11-09 | バイエル ファーマ アクチエンゲゼルシャフト | ピペリジニルピラゾロピリミジノン類及びそれらの使用 |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| KR102662215B1 (ko) | 2014-11-06 | 2024-05-02 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| EP3317282B1 (en) * | 2015-07-01 | 2020-12-09 | Northwestern University | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
| WO2017040879A1 (en) * | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy |
| US20190092789A1 (en) * | 2015-09-04 | 2019-03-28 | Lysosomal Therapeutics Inc. | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders |
| PH12018500554B1 (en) | 2015-09-14 | 2024-01-24 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
| EP3429590A4 (en) * | 2016-03-16 | 2020-02-19 | Lysosomal Therapeutics Inc. | METHOD AND COMPOSITIONS FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE IN A SUBJECT CARRIING THE SPHINGOLIPIDOSIS GENE |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| JP7034935B2 (ja) * | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| WO2017176961A1 (en) * | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US11192892B2 (en) | 2016-04-06 | 2021-12-07 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
| US20190389865A1 (en) * | 2016-05-05 | 2019-12-26 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| WO2017192930A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2018083085A1 (en) * | 2016-11-02 | 2018-05-11 | F. Hoffmann-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| MY205416A (en) * | 2017-07-28 | 2024-10-21 | Takeda Pharmaceuticals Co | Tyk2 inhibitors and uses thereof |
| CA3071534A1 (en) | 2017-08-02 | 2019-02-07 | Northwestern University | Substituted fused pyrimidine compounds and uses thereof |
| CA3072362A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| EP3747885A4 (en) | 2018-01-31 | 2021-11-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| SG11202011299PA (en) | 2018-05-17 | 2020-12-30 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| US10882865B2 (en) | 2018-08-31 | 2021-01-05 | Northwestern University | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity |
| ES2938751T3 (es) | 2018-09-10 | 2023-04-14 | Lilly Co Eli | Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico |
| MY209034A (en) | 2018-10-05 | 2025-06-17 | Forma Therapeutics Inc | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
| CN113271940A (zh) * | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| CN115003383B (zh) * | 2019-08-21 | 2024-10-01 | 斯克里普斯研究学院 | 干扰素基因刺激物sting的双环激动剂 |
| AU2020349519A1 (en) | 2019-09-17 | 2022-03-17 | Bial-R&D Investments, S.A. | Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments |
| CA3150906A1 (en) | 2019-09-17 | 2021-03-25 | Renato T. Skerlj | Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders |
| KR20220100858A (ko) | 2019-09-17 | 2022-07-18 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도 |
| AU2020393174A1 (en) * | 2019-11-25 | 2022-06-30 | Gt Gain Therapeutics Sa | Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase |
| AR121251A1 (es) | 2020-02-12 | 2022-05-04 | Lilly Co Eli | Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003284886A1 (en) | 2002-10-21 | 2004-05-13 | William E. Balch | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE |
| JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| EP1615697A2 (en) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| CA2545435C (en) | 2003-11-12 | 2014-08-19 | Amicus Therapeutics Inc. | Hydroxy piperidine derivatives to treat gaucher disease |
| US7488721B2 (en) * | 2004-05-13 | 2009-02-10 | Mcmaster University | Real time methylumbelliferone-based assay |
| NZ551424A (en) * | 2004-05-14 | 2009-10-30 | Childrenaes Cancer Inst Austra | Small molecule inhibitors for MRP1 and other multidrug transporters |
| ATE383361T1 (de) | 2004-06-21 | 2008-01-15 | Hoffmann La Roche | Pyrrazolopyrimidinderivate |
| DE102005007534A1 (de) * | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| WO2006128184A2 (en) | 2005-05-20 | 2006-11-30 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
| US20070155737A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| EP1917262B1 (en) | 2005-08-15 | 2011-12-14 | F. Hoffmann-La Roche AG | Piperidine and piperazine derivatives as p2x3 antagonists |
| KR101071438B1 (ko) * | 2005-10-21 | 2011-10-10 | 미쓰비시 타나베 파마 코퍼레이션 | 카나비노이드 수용체 길항제로서의피라졸로[1,5-ａ]피리미딘 화합물 |
| ATE517874T1 (de) | 2005-10-21 | 2011-08-15 | Exelixis Inc | Pyrimidinone als modulatoren von caseinkinase ii (ck2) |
| WO2008054947A2 (en) | 2006-10-02 | 2008-05-08 | The Brigham And Women's Hospital, Inc. | Structure of acid beta-glucosidase and methods for identifying therapeutic agents |
| US20090275586A1 (en) | 2006-10-06 | 2009-11-05 | Kalypsys, Inc. | Heterocyclic inhibitors of pde4 |
| US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| EP2139323B1 (en) | 2007-04-13 | 2013-08-21 | Amicus Therapeutics, Inc. | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| US20090215778A1 (en) | 2007-04-27 | 2009-08-27 | Panacos Pharmaceuticals, Inc. | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives |
| WO2008144591A2 (en) | 2007-05-16 | 2008-11-27 | The Brigham And Women's Hospital, Inc. | Treatment of synucleinopathies |
| WO2008154207A1 (en) | 2007-06-08 | 2008-12-18 | The Burnham Institute For Medical Research | Methods and compounds for regulating apoptosis |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| WO2009049421A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009152083A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
| JP2011526925A (ja) | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| WO2010086040A1 (en) * | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| BR112013014242B1 (pt) | 2010-12-08 | 2022-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composição farmacêutica e composto ou seu sal farmaceuticamente aceitável |
| KR102662215B1 (ko) * | 2014-11-06 | 2024-05-02 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 |
-
2011
- 2011-12-08 BR BR112013014242-1A patent/BR112013014242B1/pt active IP Right Grant
- 2011-12-08 CA CA2820362A patent/CA2820362C/en active Active
- 2011-12-08 US US13/991,816 patent/US9353117B2/en active Active
- 2011-12-08 MX MX2018000385A patent/MX385600B/es unknown
- 2011-12-08 HR HRP20220512TT patent/HRP20220512T1/hr unknown
- 2011-12-08 PT PT118107143T patent/PT2649075T/pt unknown
- 2011-12-08 MX MX2013006462A patent/MX354506B/es active IP Right Grant
- 2011-12-08 ES ES18165005T patent/ES2912284T3/es active Active
- 2011-12-08 KR KR1020137017520A patent/KR101931224B1/ko active Active
- 2011-12-08 PT PT181650052T patent/PT3366688T/pt unknown
- 2011-12-08 AU AU2011338377A patent/AU2011338377B2/en active Active
- 2011-12-08 SI SI201132052T patent/SI3366688T1/sl unknown
- 2011-12-08 PL PL18165005T patent/PL3366688T3/pl unknown
- 2011-12-08 ES ES11810714.3T patent/ES2681218T3/es active Active
- 2011-12-08 EP EP11810714.3A patent/EP2649075B1/en active Active
- 2011-12-08 SI SI201131532T patent/SI2649075T1/sl unknown
- 2011-12-08 RU RU2013126094/04A patent/RU2603637C2/ru active
- 2011-12-08 DK DK18165005.2T patent/DK3366688T3/da active
- 2011-12-08 DK DK11810714.3T patent/DK2649075T3/en active
- 2011-12-08 LT LTEP18165005.2T patent/LT3366688T/lt unknown
- 2011-12-08 TR TR2018/10523T patent/TR201810523T4/tr unknown
- 2011-12-08 WO PCT/US2011/063928 patent/WO2012078855A1/en not_active Ceased
- 2011-12-08 RS RS20220422A patent/RS63320B1/sr unknown
- 2011-12-08 PL PL11810714T patent/PL2649075T3/pl unknown
- 2011-12-08 JP JP2013543335A patent/JP6154746B2/ja active Active
- 2011-12-08 EP EP18165005.2A patent/EP3366688B1/en active Active
- 2011-12-08 CN CN201180066859.7A patent/CN103534255B/zh active Active
- 2011-12-08 HU HUE11810714A patent/HUE038635T2/hu unknown
-
2013
- 2013-06-06 IL IL226767A patent/IL226767B/en active IP Right Grant
- 2013-06-07 ZA ZA2013/04215A patent/ZA201304215B/en unknown
-
2016
- 2016-04-28 US US15/141,275 patent/US9974789B2/en active Active
-
2018
- 2018-05-18 US US15/983,844 patent/US10925874B2/en active Active
- 2018-05-28 IL IL259648A patent/IL259648B/en active IP Right Grant
-
2022
- 2022-05-04 CY CY20221100316T patent/CY1125186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220512T1 (hr) | Supstituirani pirazolopirimidini kao aktivatori glukocerebrozidaze | |
| ES2439501T3 (es) | Compuestos triazolopiridina como inhibidores de la cinasa PIM | |
| HRP20200624T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka | |
| JP2014523881A5 (enExample) | ||
| ES2821529T3 (es) | Derivados de 4,6-diamino-pirimidina como inhibidores de Bmi-1 para el tratamiento del cáncer | |
| ES2704704T3 (es) | Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden | |
| JP6509386B2 (ja) | ｍＴＯＲ経路関連疾患を治療するための化合物 | |
| NZ703111A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
| TW201026702A (en) | Mtor kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | |
| TW200900405A (en) | Substituted imidazopyridazines as lipid kinase inhibitors | |
| AU2020371295A1 (en) | Pharmaceutical combination of PRMT5 inhibitors | |
| NZ613235A (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
| HRP20161714T1 (hr) | Inhibitori kinaze | |
| NZ587051A (en) | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) | |
| RU2012120288A (ru) | Новые производные нафтиридина и их применение в качестве ингибиторов киназы | |
| HRP20170103T1 (hr) | Triazolopiridazini kao modulatori tirozin kinaze | |
| PE20090049A1 (es) | Derivados de piridopirimidina como moduladores de la actividad de pde 4 | |
| SI2041133T1 (sl) | Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki | |
| JP2013510120A5 (enExample) | ||
| AR081072A1 (es) | Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia | |
| ME02922B (me) | Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže | |
| JP6738962B2 (ja) | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 | |
| KR20190017756A (ko) | 암 치료용 약학적 조합물 | |
| HRP20140206T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20210095T1 (hr) | Novi derivati amino-imidazopiridina kao inhibitori janus kinaze i njihova farmaceutska upotreba |